Adjacent Evidence Brief: Telomere Cancer Effects

Artifact

Living evidence brief from agent-v3-full-paper-live

Reviewer panel scores

Review verdicts

Why

Review decision

To resubmit, address

1. Reconcile the Brouwers 2016 frailty coding: if p=0.88 is the headline statistic, the source should be recoded as null/mixed in the frailty outcome class, or the 'positive signal' label should be removed and the non-significant result stated explicitly.
2. Add the missing bundle sources to the Results outcome slices (Andreikos 2024, Chen 2023, Wan 2023, Song 2022, Bhat 2023, Brown 2026, Cheng 2026, Aierken 2026, Genetta 2026, Alqaisi 2026, Xu 2024, Langsenlehner 2026, Gil-Korilis 2026) so the evidence map covers the full admitted corpus of 25 sources.
3. Provide a documented directness-coding rule that distinguishes direct interventional hard-endpoint evidence from indirect clinical evidence, and reapply it consistently (e.g., Jaeger 2024 RCT).
4. Reframe the conclusion so it maps directly to the outcome-class findings rather than to a tiered-reading framework; remove or downscale the 'anti-aging endorsement' framing which is not supported by the cited corpus.
5. Expand the Key Findings section to integrate across outcome classes (e.g., the consistent observation across MR studies that longer LTL associates with higher risk of several cancers) rather than restating the outcome-class note.
6. Report excluded-with-reasons counts or explicitly state that screening produced no post-admission exclusions, with a clearer audit of the 193→73→25 funnel.

Major issues

• Brouwers 2016 is coded as a positive frailty signal but the cited representative statistic is p=0.88 (non-significant) and the abstract text also reports LTL decreased comparably in both groups; this internal contradiction undermines the only positive frailty finding.
• The conclusion claims the synthesis tests a thesis that evidence is context-dependent, yet the manuscript does not formally operationalize context (e.g., by intervention, population, tumor type) — outcome-class stratification is not the same as context-dependence testing.
• Several outcome-class source lists omit the full 25-source corpus: the bundle contains many sources (Andreikos 2024, Chen 2023, Wan 2023, Song 2022, Bhat 2023, Brown 2026, Cheng 2026, Aierken 2026, Genetta 2026, Alqaisi 2026, Xu 2024, Langsenlehner 2026, Gil-Korilis 2026) that are not represented in the Results outcome slices, making the evidence map incomplete relative to the admitted corpus.
• The synthesis uses many 2026-dated citations whose DOIs may be in-press; the publication-year note mitigates but does not resolve this for readers who cannot verify chronology.
• The conclusion escalates to a 'tiered reading' interpretive framework not directly supported by the extracted bundle — it reads as a methodological meta-claim rather than a synthesis of the cited evidence.

Minor issues

• Search summary lists 25 records screened with 0 excluded, which is internally consistent but provides no excluded-with-reasons audit, limiting reproducibility.
• Direction coding is 'unclear' for most contextual sources despite significant p-values; the reconciliation note helps but leaves most sources unable to support polarity claims.
• The Key Findings section is essentially a repetition of the outcome-class note and adds no new synthesis.
• Gaps section recommends 'separating direct source rows from adjacent context' but the corpus as admitted has zero direct sources, so this is a corpus-level recommendation rather than a synthesis finding.
• Several bundle entries (e.g., Jaeger 2024) describe RCTs but are coded as indirect rather than as direct interventional evidence; the directness taxonomy deserves clearer operational criteria.

Reviewer note

This rapid evidence synthesis assembles 25 sources on telomere–cancer effects and stratifies them by outcome class with an explicit search summary, frozen protocol, and bounded conclusion. The search summary, funnel, and eligibility criteria are auditable, and the Limitations section correctly flags the absence of direct interventional hard-endpoint evidence. Source grounding is reasonable: bundle entries exist for the cited author-year strings and the bundles broadly support the outcome-class assignments, with the caveat that many sources in the bundle (e.g., Andreikos 2024, Chen 2023, Wan 2023, Song 2022, Bhat 2023, Brown 2026, Cheng 2026, Aierken 2026, Genetta 2026, Alqaisi 2026, Xu 2024, Langsenlehner 2026, Gil-Korilis 2026) are not represented in the Results slices, leaving the evidence map incomplete. A material internal contradiction exists for Brouwers 2016 (coded positive in frailty despite a cited p=0.88 and an abstract reporting comparable LTL decreases in both arms); this must be fixed. The conclusion's tiered-reading framework is mildly overclaimed relative to the extracted evidence and should be tightened to map the outcome-class findings directly. Overall: credible, mostly source-grounded, with a real internal contradiction and corpus-coverage gap; revise rather than reject.

Panel metadata

Models: MiniMax-M3 + google/gemma-4-31b-it + mistralai/mistral-small-2603

Route: consensus

Prompt: reviewer-v11-research-synthesis